Cti Biopharma Corp Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CTI BIOPHARMA CORP, and when can generic versions of CTI BIOPHARMA CORP drugs launch?
CTI BIOPHARMA CORP has one approved drug.
There are three US patents protecting CTI BIOPHARMA CORP drugs.
There are sixty-six patent family members on CTI BIOPHARMA CORP drugs in twenty-seven countries.
Summary for Cti Biopharma Corp
| International Patents: | 66 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Cti Biopharma Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | 8,153,632 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | 8,980,873 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | 9,573,964 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
